Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 4Squamous Intraepithelial Lesions 4Uterine Cervical Dysplasia 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Vaginal Neoplasms 1Recurrence 1Penile Neoplasms 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Squamous Cell Cancer 1HIV Seropositivity 1Anal Canal Carcinoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 29Papillomavirus Vaccines 22Vaccines 11Human Papillomavirus Recombinant Vaccine nonavalent 11Radiotherapy, Intensity-Modulated 7Human Papillomavirus DNA Tests 7Colposcopy 7Cisplatin 7Educational Status 6Carboplatin 6Blood Specimen Collection 6Vaccines, Synthetic 5Specimen Handling 5Early Intervention, Educational 5Vaginal Smears 4Methods 4Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Surveys and Questionnaires 3Patient Navigation 3Paclitaxel 3Imiquimod 3Hepatitis A Vaccines 3Cyclophosphamide 3halofantrine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Papillomavirus Infections × VGX-3100 × Clear all
NCT00685412 2017-09-13

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Inovio Pharmaceuticals

Phase 1 Completed
18 enrolled
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡